What's Going On With TG Therapeutics (TGTX) Stock?

TG Therapeutics, Inc. TGTX shares are moving higher on Friday.

What To Know:

TG Therapeutics launched Briumvi, a drug for the treatment of relapsing forms of MS, in the first quarter of 2023.  The company reported first quarter product revenue from Briumvi alone at $7.8 million and projected continued revenue growth for the drug. 

According to data from Benzinga Pro, TGTX has considerable short interest with 18.59% of available shares currently being sold short.  TGTX stock is also receiving attention from retail investors with the stock currently listed as a top trending ticker on StockTwits and Yahoo!.

Related News: Prestige Wealth Management (PWM) Stock Is Ripping Higher: What's Going On?

TGTX Price Action: According to Benzinga Pro, TG Therapeutics shares are trading 11% higher at $25.58 at the time of publication.

Image: akirEVarga from Pixabay